Tirzepatide + Semaglutide

Co-formulated lyophilized blend of tirzepatide (a dual GIP/GLP-1 receptor agonist 39-mer) and semaglutide (a GLP-1 receptor agonist 31-mer).

Reconstitution. For in-vitro laboratory handling, dissolve with bacteriostatic water (0.9% benzyl alcohol). Compound is hygroscopic — handle in low-humidity conditions and re-cap immediately.

Stability profile. Lyophilized: stable at room temperature for up to 30 days sealed; long-term storage at -20 °C recommended. Reconstituted material: stable at 2–8 °C for up to 14 days.

Selected primary literature.
- Sikiric P et al., 1993, J Physiol Paris 87:313 — original BPC-157 sequence characterization.
- Goldstein AL et al., 2005, Expert Opin Biol Ther 5(11):1505 — review of thymosin β-4 structural biology.

What remains uncharacterized: per-component concentration-response in any specific in-vitro model system is not implied here. Components are individually characterized in the structural-class literature cited above.

For research use only. Not for human or animal consumption.

By placing an order with Verified Compounds, you acknowledge and confirm that:
- All products are intended exclusively for in-vitro research and laboratory use only.
- Products are not intended for human or animal consumption, nor for diagnostic, therapeutic, or clinical applications.
- You are familiar with your jurisdiction's regulations regarding research chemicals and their proper handling.
- You understand the safety protocols required for handling research peptides and will ensure proper storage.
- You are at least 21 years of age and represent a qualified research institution or are a licensed researcher.
- Verified Compounds, this website, and our affiliates are not responsible for how you use or store these items once delivered, to the fullest extent allowed by law.